HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

This month's Leading Edge editorial discusses the difference between perception of risk and the actual risk by drawing upon two recent examples: breast cancer and the pill, and cannabis smoking and cancer risk. In both situations, scientific evidence does not appear to be affecting the public's misperception of absolute risk, and more worryingly, in the case of cannabis smoking, even nationwide policy is being lead by personal views rather than scientific evidence.

The editorial concludes: "Unravelling a misguided perception of risk from the real facts is a difficult task, but it is essential if the perpetuation of poorly conceived ideas is to stop. In light of the current trend towards chemoprevention to reduce a person's risk of contracting cancer, it is important that the general public do not become disenfranchised from the medical community by exposure to over-reporting of contradictory reports in the popular media. Only then will cancer risk truly decrease by informed changes in lifestyle."

Reviews:

Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention

Cigarette smoking and the risk of endometrial cancer

Strategic marketing in the UK tobacco industry

Hyperthermia in combined treatment of cancer

Metastasis to and from the central nervous system-the "relatively protected site"

Stem-cell origin of metastasis and heterogeneity of solid tumours

The Lancet Infectious Diseases (TLID)

Combination antiretroviral therapies are widely used for the treatment of HIV but it is unclear whether they will continue to be effective in the face of quickly evolved drug-resistant strains of HIV, and increased risky sexual behaviour in certain communities. In the August issue of The Lancet Infectious Diseases, J X Velasco-Hernandez and colleagues, from the Instituto Mexicano del Petroleo, San Bartolo, Mexico, and the UCLA School of Medicine, Los Angeles, US
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
31-Jul-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO and the Lancet Infectious Diseases TLID

(Date:10/31/2014)... 2014 Energy Textiles has recently added ... gear is now available online, and Energy Textile is ... Celliant infrared-active athletic gear over compression gear. , ... has been signed for Under Armour to provide team ... eight years. In light of this decision, Energy Textiles ...
(Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
(Date:10/31/2014)... Gold Medal Wine Club is making it ... for the wine novice and enthusiasts on their lists with ... , which Early Bird shoppers receive discounts as high as ... , Gift Givers must place their orders before November ... Gold Medal Wine Club adds more value to its Wine ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
(Date:10/31/2014)... 2014 Triple Board Certified surgeon ... services to transform the appearance of military veteran Joseph ... of Facial Plastic and Reconstruction Surgery (AAFPRS) Faces of ... the facial hair Jones lost during an IED blast ... hair restoration procedure, valued around $16,000, took Dr. Epstein ...
Breaking Medicine News(10 mins):Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2
(Date:10/31/2014)... , Oct. 31, 2014  Digirad Corporation (Nasdaq: DRAD) today ... Inc. (Nasdaq: PDII ), a healthcare commercialization ... proposal to acquire the company.  Digirad ... regarding a transaction and to operate in the ordinary ... or take on additional debt, on acquisitions or other ...
(Date:10/31/2014)... -- Grammy Award-winner Bruce Hornsby will give an ... actors, and musicians during the 10 th Annual ... Mandarin Oriental Hotel in New York City ... individuals who embody the values of the Orthopaedic Foundation. ... honor, the Spirit of an Active Lifestyle Award, to ...
(Date:10/31/2014)... Oct. 31, 2014  Australian biopharmaceutical company Specialised Therapeutics ... (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be ... with metastatic pancreatic cancer from 1 November. ... is the 5 th most common cause of ... cancer deaths, with the lowest 5-year survival of all ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 510th Anniversary Orthopaedic Foundation Gala Set For Success 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8
Cached News: